Synergistic combination of aztreonam and ceftazidime/avibactam against resistant Stenotrophomonas maltophilia on pancreatitis

被引:8
|
作者
Torres, Natalia de Almeida [1 ,3 ]
Morales Junior, Ronaldo [1 ]
Lopes, Luis Fernando Bueno [1 ]
Zeigler, Rogerio [2 ]
Uip, David Everson [2 ]
机构
[1] Sirio Libanes Hosp, Dept Clin Pharm, Sao Paulo, Brazil
[2] Sirio Libanes Hosp, Sao Paulo, Brazil
[3] Sirio Libanes Hosp, Pharm Dept, Rua Dona Adma Jafet,91,Bela Vista, Sao Paulo, SP, Brazil
来源
JOURNAL OF INFECTION IN DEVELOPING COUNTRIES | 2023年 / 17卷 / 06期
关键词
Stenotrophomonas maltophilia; bacterial resistance; nosocomial infection; INFECTION;
D O I
10.3855/jidc.17290
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Introduction: Stenotrophomonas maltophilia is a Gram-negative, opportunistic pathogen associated with a high morbidity and mortality rate. We report our clinical experience in treating a patient with infected pancreatic necrosis caused by multidrug-resistant (MDR) S. maltophilia with a novel drug combination. Case report: A 65-year-old male with history of type II diabetes was admitted with acute pancreatitis, voluminous ascites, and signs of sepsis after undergoing an echo-endoscopy procedure with pancreas biopsy to investigate a Wirsung duct dilatation. Retroperitoneal fluid culture revealed S. maltophilia resistant to colistin and with intermediate susceptibility to trimethoprim-sulfamethoxazole and levofloxacin. The synergy between aztreonam (ATM) and ceftazidime/avibactam (CZA) was demonstrated using the combined disk pre-diffusion test. Conclusions: There are sparse data providing guidance on the optimal regimen against MDR S. maltophilia infections. Although in this case a surgical excision was essential, combination of ATM and CZA provided effective synergistic antimicrobial treatment with clinical cure of severe acute pancreatitis infected with S. maltophilia. The combined disk pre-diffusion test with ATM and CZA requires no special equipment and can be routinely performed in clinical microbiology labs. Combination of ATM with CZA should be considered for cases of MDR S. maltophilia infections with limited treatment options.
引用
收藏
页码:881 / 885
页数:5
相关论文
共 50 条
  • [1] In Vitro Comparison of Aztreonam/Amoxicillin-Clavulanate Versus Aztreonam/Ceftazidime-Avibactam on Ceftazidime-Avibactam Resistant Stenotrophomonas maltophilia
    Cremet, Lise
    Joffraud, Leo
    Eschapasse, Emmanuel
    Bihouee, Tiphaine
    Tissot, Adrien
    Gibaud, Sophie
    Persyn, Elise
    MICROBIAL DRUG RESISTANCE, 2022, 28 (08) : 877 - 881
  • [2] Looking for Stenotrophomonas maltophilia treatment: in vitro activity of ceftazidime/avibactam alone and in combination with aztreonam
    Ranieri, Enrica Maddalena
    Denicolo, Sofia
    Stolfa, Stefania
    Dalfino, Lidia
    Bavaro, Davide Fiore
    Saracino, Annalisa
    Ronga, Luigi
    Del Prete, Raffaele
    Mosca, Adriana
    JOURNAL OF CHEMOTHERAPY, 2023, 35 (07) : 610 - 613
  • [3] Activity of Aztreonam in Combination with Avibactam, Clavulanate, Relebactam, and Vaborbactam against Multidrug-Resistant Stenotrophomonas maltophilia
    Biagi, M.
    Lamm, D.
    Meyer, K.
    Vialichka, A.
    Jurkovic, M.
    Patel, S.
    Mendes, R. E.
    Bulman, Z. P.
    Wenzler, E.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2020, 64 (12)
  • [4] In vitro activity of aztreonam-avibactam combination against blood culture isolates of Stenotrophomonas maltophilia in Japan before the launch of ceftazidime-avibactam
    Aoki, Wataru
    Uwamino, Yoshifumi
    Kamoshita, Yuka
    Inose, Rika
    Nagata, Mika
    Hasegawa, Naoki
    Matsushita, Hiromichi
    MICROBIOLOGY SPECTRUM, 2025,
  • [5] Stenotrophomonas maltophilia susceptibility to ceftazidime-avibactam combination versus ceftazidime alone
    Moriceau, C.
    Eveillard, M.
    Lemarie, C.
    Chenouard, R.
    Pailhories, H.
    Kempf, M.
    MEDECINE ET MALADIES INFECTIEUSES, 2020, 50 (03): : 305 - 307
  • [6] Synergistic combination of ceftazidime and avibactam with Aztreonam against MDR Klebsiella pneumoniae in ICU patients
    Khattab, Sally
    Askar, Aya Mohamed
    Abdellatif, Hidi A. A.
    Othman, Amira A. A.
    Rayan, Amal H.
    Azab, Hasnaa
    SCIENTIFIC REPORTS, 2025, 15 (01):
  • [7] Enhancement and Comparison of (Ceftazidime-)Avibactam Plus Aztreonam Susceptibility Tests for Stenotrophomonas maltophilia in Clinical Diagnostics
    Vlaspolder, Gro L.
    Hughes, Laura A.
    in 't Veld, Robert A. G. Huis
    Kampinga, Greetje A.
    Bathoorn, Erik
    CURRENT MICROBIOLOGY, 2024, 81 (01)
  • [8] Enhancement and Comparison of (Ceftazidime-)Avibactam Plus Aztreonam Susceptibility Tests for Stenotrophomonas maltophilia in Clinical Diagnostics
    Gro L. Vlaspolder
    Laura A. Hughes
    Robert A. G. Huis in ’t Veld
    Greetje A. Kampinga
    Erik Bathoorn
    Current Microbiology, 2024, 81
  • [9] Successful treatment of Stenotrophomonas maltophilia with ceftazidime-avibactam and aztreonam in an individual with cystic fibrosis: A case report
    Duehlmeyer, Stephanie
    Meier, Ellen
    Oermann, Christopher
    PEDIATRIC PULMONOLOGY, 2025, 60 (01)
  • [10] Avibactam Restores the Susceptibility of Clinical Isolates of Stenotrophomonas maltophilia to Aztreonam
    Mojica, Maria F.
    Papp-Wallace, Krisztina M.
    Taracila, Magdalena A.
    Barnes, Melissa D.
    Rutter, Joseph D.
    Jacobs, Michael R.
    LiPuma, John J.
    Walsh, Thomas J.
    Villa, Alejandro J.
    Bonomo, Robert A.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2017, 61 (10)